Alembic Pharmaceuticals Ltd. (APLLTD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Acutaas Chemical

Neuland Labs.

ERIS Lifescience

Natco Pharma

Sai Life

Jubilant Pharmo

Alembic Pharma

Caplin Point Lab

Cohance Life

Concord Biotech

OneSource Speci.

Why is Alembic Pharmaceuticals Ltd. ?

Poor long term growth as Operating profit has grown by an annual rate -8.80% of over the last 5 years

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 1.93% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -18.24% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Alembic Pharma for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Alembic Pharma

-18.15%

-0.52

35.06%

Sensex

4.78%

0.39

11.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.32%

EBIT Growth (5y)

-8.80%

EBIT to Interest (avg)

24.86

Debt to EBITDA (avg)

0.93

Net Debt to Equity (avg)

0.25

Sales to Capital Employed (avg)

1.02

Tax Ratio

19.38%

Dividend Payout Ratio

37.06%

Pledged Shares

Institutional Holding

20.34%

ROCE (avg)

12.71%

ROE (avg)

11.80%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

3.34

EV to EBIT

22.75

EV to EBITDA

16.93

EV to Capital Employed

2.87

EV to Sales

2.70

PEG Ratio

Dividend Yield

1.22%

ROCE (Latest)

12.61%

ROE (Latest)

11.93%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

No Trend

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

15What is working for the Company

OPERATING PROFIT TO INTEREST(Q)

Highest at 13.03 times

PBDIT(Q)

Highest at Rs 315.69 cr.

PBT LESS OI(Q)

At Rs 216.81 cr has Grown at 43.76%

NET SALES(Q)

Highest at Rs 1,910.15 cr

OPERATING PROFIT TO NET SALES(Q)

Highest at 16.53%

PAT(Q)

At Rs 184.71 cr has Grown at 29.6%

EPS(Q)

Highest at Rs 9.40

-9What is not working for the Company

OPERATING CF(Y)

Lowest at Rs 87.95 Cr

INTEREST(9M)

At Rs 72.27 cr has Grown at 33.22%

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.79 times

DEBT-EQUITY RATIO(HY)

Highest at 0.28 times

Loading Valuation Snapshot...

Here's what is working for Alembic Pharma

Operating Profit to Interest - Quarterly

Highest at 13.03 times

in the last five quarters

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit (PBDIT) - Quarterly

Highest at Rs 315.69 cr. and Grown

each quarter in the last five quarters

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

Highest at Rs 216.81 cr. and Grown

each quarter in the last five quarters

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly

At Rs 216.81 cr has Grown at 43.76%

Year on Year (YoY)

MOJO Watch

Near term PBT trend is very positive

PBT less Other Income (Rs Cr)

Net Sales - Quarterly

Highest at Rs 1,910.15 cr

in the last five quarters

MOJO Watch

Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit Margin - Quarterly

Highest at 16.53%

in the last five quarters

MOJO Watch

Company's efficiency has improved

Operating Profit to Sales

Profit After Tax (PAT) - Quarterly

Highest at Rs 184.71 cr.

in the last five quarters

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly

At Rs 184.71 cr has Grown at 29.6%

Year on Year (YoY)

MOJO Watch

Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly

Highest at Rs 9.40

in the last five quarters

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Alembic Pharma

Inventory Turnover Ratio- Half Yearly

Lowest at 2.79 times and Fallen

each half year in the last five half yearly periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Interest - Nine Monthly

At Rs 72.27 cr has Grown at 33.22%

over preceding nine months period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Operating Cash Flow - Annually

Lowest at Rs 87.95 Cr

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (Rs Cr)

Debt-Equity Ratio - Half Yearly

Highest at 0.28 times

in the last five half yearly periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio